Completed PHASE4 INTERVENTIONAL 2-arm NCT00395863

Multihance at 3 Tesla (3T) in Brain Tumors

A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T

Sponsor: Bracco Diagnostics, Inc

Conditions Brain Tumor

Interventions Arm 2 - Magnevist Multihance

Updated 7 times since 2017 Last updated: Oct 14, 2020 Started: Nov 30, 2006 Primary completion: Feb 29, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Brain Tumor, this trial is completed. The trial is conducted by Bracco Diagnostics, Inc and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2020 — Jan 2021 [monthly]

Completed PHASE4
Oct 2020 — Dec 2020 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Oct 2020 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bracco Diagnostics, Inc

Data source: Bracco Diagnostics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States